重组人Ⅱ型TNF受体-抗体融合蛋白联合风湿骨痛片对类风湿性关节炎患者的疗效观察  

Clinical observation of recombinant human TNF receptor type Ⅱ-antibody fusion protein combined with Fengshigutong tablets on rheumatoid arthritis patients

作　　者：刘洪波[1] 靖春颖[2] 韩平 LIU Hong-bo;JING Chun-ying;HAN Ping(Department of Traditional Chinese Medicine,the First Affiliated Hospital of Hainan Medical University;College of Traditional Chinese Medicine,Hainan Medical University,Haikou 571199,Hainan,China)

机构地区：[1]海南医学院第一附属医院中医科 [2]海南医学院中医学院,海南海口571199

出　　处：《川北医学院学报》2019年第4期358-361,376,共5页Journal of North Sichuan Medical College

基　　金：国家中医药管理局第六批全国老中医药专家学术经验继承项目(2017-29号)

摘　　要：目的:探究重组人Ⅱ型肿瘤坏死因子(TNF)受体-抗体融合蛋白联合风湿骨痛片对类风湿性关节炎(RA)患者的疗效。方法:将90例RA患者随机分为观察组和对照组,每组各45例。对照组给予注射重组人Ⅱ型TNF受体-抗体融合蛋白;观察组注射重组人Ⅱ型TNF受体-抗体融合蛋白联合口服风湿骨痛片。比较两组患者的血清炎症因子、炎性指标、临床疗效、美国健康评估问卷(HAQ)、RA28处关节疾病活动度评分(DAS28)。结果:治疗后,两组患者的IL-6、TNF-α水平比治疗前低,IL-10比治疗前高( P <0.05),观察组的IL-6、TNF-α水平低于对照组,IL-10水平高于对照组( P <0.05);两组患者的类风湿因子(RF)、红细胞沉降率(ESR)、C反应蛋白(CRP)炎性指标均较治疗前更低( P<0.05),且观察组低于对照组(P <0.05);观察组患者临床疗效总有效率为93.33%,高于对照组的73.33%( P <0.05);两组患者HAQ 评分、DAS28及症状积分较治疗前更低( P <0.05),且观察组患者HAQ 评分、DAS28 评分及症状积分低于对照组( P <0.05)。结论:对RA患者采用注射重组人Ⅱ型TNF受体-抗体融合蛋白联合口服风湿骨痛片治疗,提高了临床治疗效果和患者生活质量,减轻了患者的痛苦。Objective:To explore the therapeutic effect of recombinant human tumor necrosis factor(TNF) receptor type Ⅱ antibody fusion protein combined with Fengshigutong tablet on rheumatoid arthritis(RA) patients.Methods:90 patients with RA were randomly divided into the observation group and the control group,45 cases in each group.The control group was injected with recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein,while the observation group was injected with recombinant human type Ⅱ tumor necrosis factor receptor-antibody fusion protein combined with oral rheumatalgia tablets.The serum inflammatory factors,clinical efficacy,American health assessment questionnaire(HAQ) and RA28 joint disease activity score(DAS28) of the two groups were compared.Results:After treatment,the levels of interleukin-6(IL-6) and TNF-α in the two groups were lower than those before treatment,and the levels of IL-10 were higher than those before treatment(P<0.05).The levels of IL-6 and TNF-α in the observation group were lower than those in the control group,and the levels of IL-10 were higher than those in the control group(P<0.05).The inflammatory indexes of rheumatoid factor(RF),erythrocyte sedimentation rate(ESR) and C-reactive protein(CRP) in the two groups were lower than those before treatment(P<0.05),and those in the observation group were lower than those in the control group(P<0.05).The total effective rate of the observation group was 93.33%,which was higher than that of the control group(73.33%,P<0.05).The HAQ score,DAS28 and symptom score of the two groups were lower than those before treatment(P<0.05),and the HAQ score,DAS28 score and symptom score of the observation group were lower than those of the control group(P<0.05).Conclusion:Injection of recombinant human TNF receptor type Ⅱ antibody fusion protein combined with oral administration of Fengshigutong tablets for RA patients improves the clinical therapeutic effect,greatly reduces the pain of patients and improves the quality of life

关 键 词：重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白 风湿骨痛片 类风湿 关节炎 血清炎症因子 临床疗效 

分 类 号：R259.9[医药卫生—中西医结合]